Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
172.2 INR | +3.18% | -1.26% | +7.06% |
Apr. 18 | Marksans Pharma's Goa Facility Gets Five Inspectional Observations from US FDA | MT |
Feb. 14 | Transcript : Marksans Pharma Limited, Q3 2024 Earnings Call, Feb 14, 2024 |
Sales 2024 * | 21.58B 259M | Sales 2025 * | 26.33B 316M | Capitalization | 75.75B 909M |
---|---|---|---|---|---|
Net income 2024 * | 3.34B 40.04M | Net income 2025 * | 4.07B 48.82M | EV / Sales 2024 * | 3.51 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.88 x |
P/E ratio 2024 * |
22.7
x | P/E ratio 2025 * |
18.6
x | Employees | 852 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 55.99% |
Latest transcript on Marksans Pharma Limited
1 day | +3.18% | ||
1 week | -1.26% | ||
Current month | +13.63% | ||
1 month | +19.46% | ||
3 months | +19.75% | ||
6 months | +64.08% | ||
Current year | +7.06% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 52 | 92-04-15 | |
Director of Finance/CFO | 54 | 02-09-05 | |
Compliance Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Sunny Sharma
BRD | Director/Board Member | 49 | 21-08-10 |
Chief Executive Officer | 52 | 92-04-15 | |
Director/Board Member | 52 | 14-09-24 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 172.2 | +3.18% | 181 747 |
24-04-25 | 166.9 | -0.57% | 92,766 |
24-04-24 | 167.8 | -0.94% | 98,746 |
24-04-23 | 169.4 | +0.95% | 144,938 |
24-04-22 | 167.8 | -3.76% | 340,585 |
Delayed Quote Bombay S.E., April 26, 2024 at 06:00 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+25.04% | 556B | |
-6.33% | 354B | |
+19.90% | 331B | |
+7.95% | 296B | |
+13.47% | 233B | |
+5.61% | 201B | |
-10.18% | 193B | |
-12.26% | 143B | |
-6.47% | 144B |
- Stock Market
- Equities
- MARKSANS Stock
- MARKSANS Stock